Training grant in hemostasis and thrombosis

止血和血栓形成培训补助金

• 批准号: 9503006
• 负责人: Douglas Brock Cines
• 金额: $ 50.46万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9503006
• 关键词: Grant; Hemostatic function; Thrombosis; Training

 DESCRIPTION (provided by applicant): The University of Pennsylvania (UPENN) and Children's Hospital of Philadelphia (CHOP) have had an NHLBI- sponsored T32 training grant to support pre- and post-doctoral trainees in the interrelated areas of hemostasis, thrombosis and vascular biology for the past 14 years. These areas have great clinical importance as heart attacks and strokes remain the number one causes of mortality in our industrial society. Many other disorders, including inflammation, autoimmunity, inflammation and cancer are of considerable clinical importance and directly involve the actions of what have classically been considered components of the hemostatic system. Yet, there are insufficient talented trainees to maintain the exciting pace of basic and clinical discovery we are now experiencing in this scientific arena and to address so many unmet clinical needs. Based on our experience, we have developed a unique training program in part because of the research faculty and opportunities on the UPENN/CHOP campus in hemostasis/thrombosis/vascular biology-related research involving 28 NIH-supported investigators. This rich environment, together with what we consider to be a well designed and implemented vision for career development, has allowed this T32 to continue to attract and train talented and productive pre- and postdoctoral trainees. Our program is likely the only program in the country with its particular NHLBI focus. Its strengths include: 1) its large number of mentors with interest in the hemostasis/thrombosis/vascular biology-related aspects of angiogenesis, vascular contractility, cancer spread, biomechanics, gene delivery and embryonic stem cell development, among others. 2) A weekly benign hematology only seminar series that include about 50% speakers with scientific interests closely aligned to the mission of this T32 who meet with our trainees and attend our Super Group Laboratory Meeting to provide their advice into ongoing research on the UPENN/CHOP campus. 2) Provide formal training in translational medicine including didactic training in how to establish academic or pharmaceutical careers. 3) An emphasis on developing laboratory managerial and leadership skills to expand career options, including a structure for self-assessment, career development and bidirectional assessment of interactions with mentors and Program Directors. Thus, we believe that we provide a strong training program with an extraordinarily rich and interactive group of faculty members that provides exciting research opportunities combined with strong didactic and mentoring programs focused on today's and emerging new challenges in hemostasis/ thrombosis/vascular biology as it impacts many clinically relevant disorders. We expect that our T32 will train talented and committed individuals who will make important contributions to these areas of research and who will become national leaders in the field for years to come.

 描述（由申请人提供）：宾夕法尼亚大学（UPENN）和费城儿童医院（CHOP）在过去14年中获得了NHLBI赞助的T32培训补助金，以支持止血、血栓形成和血管生物学相关领域的博士前和博士后学员。这些领域具有很大的临床重要性，因为心脏病发作和中风仍然是我们工业社会的头号死亡原因。许多其他疾病，包括炎症、自身免疫、炎症和癌症具有相当大的临床重要性，并且直接涉及传统上被认为是止血系统组分的作用。然而，没有足够的有才华的受训者来保持我们现在在这个科学竞技场中经历的令人兴奋的基础和临床发现的步伐，并解决如此多未满足的临床需求。根据我们的经验，我们已经开发了一个独特的培训计划，部分原因是研究人员和机会在UPENN/CHOP校园止血/血栓形成/血管生物学相关的研究涉及28 NIH支持的研究人员。这种丰富的环境，加上我们认为是一个精心设计和实施的职业发展愿景，使这个T32能够继续吸引和培养有才华和生产力的博士前和博士后学员。我们的计划可能是该国唯一一个以NHLBI为重点的计划。其优势包括：1）其大量导师对血管生成、血管收缩性、癌症扩散、生物力学、基因递送和胚胎干细胞发育等止血/血栓形成/血管生物学相关方面感兴趣。2)每周一次的良性血液学研讨会系列，其中包括约50%的发言者与科学兴趣密切配合这个T32的使命谁与我们的学员见面，并参加我们的超级组实验室会议，提供他们的建议到正在进行的研究在UPENN/CHOP校园。2)提供转化医学的正式培训，包括如何建立学术或制药职业生涯的教学培训。3)强调发展实验室管理和领导技能，以扩大职业选择，包括自我评估，职业发展和与导师和项目主任互动的双向评估结构。因此，我们相信，我们提供了一个强大的培训计划，具有非常丰富和互动的教师团队，提供了令人兴奋的研究机会，结合强大的教学和指导计划，专注于当今和新兴的止血/血栓形成/血管生物学的新挑战，因为它影响了许多临床相关疾病。我们希望我们的T32将培养有才华和承诺的个人 谁将对这些研究领域作出重要贡献，谁将在未来几年成为该领域的国家领导人。